Nei Podcast

In this episode, Dr. Andy Cutler interviews Dr. Peter Weiden about when and how to switch antipsychotics in schizophrenia, tackling both the pitfalls and opportunities clinicians face in practice. They also explore how xanomeline–trospium has opened the door to treatments beyond dopamine and what this shift means for the future of care.  Peter J. Weiden, MD, is a psychiatrist and internationally recognized expert in the pharmacologic treatment of schizophrenia. His research and clinical work have focused on antipsychotic effectiveness, switching strategies, and medication adherence, with a particular emphasis on optimizing long-term outcomes for patients.   Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  N